GENESYSTEM CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,460 KRW | -7.14% |
|
+4.83% | -9.32% |
| Jun. 24 | Genesystem Co., Ltd.(KOSDAQ:A363250) dropped from S&P Global BMI Index | CI |
| Mar. 28 | Genesystem Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares. | CI |
| Sales 2021 | 13.24B 9.56M | Sales 2022 | 3.65B 2.64M | Capitalization | 58B 41.88M |
|---|---|---|---|---|---|
| Net income 2021 | 3.55B 2.56M | Net income 2022 | -9B -6.5M | EV / Sales 2021 | 3.42 x |
| Net cash position 2021 | 33.5B 24.19M | Net cash position 2022 | 22.39B 16.17M | EV / Sales 2022 | 9.75 x |
| P/E ratio 2021 |
20.7
x | P/E ratio 2022 |
-6.42
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 72.37% |
More Fundamentals
* Assessed data
More news
| 1 day | -7.14% | ||
| 1 week | +4.83% | ||
| Current month | +31.37% | ||
| 1 month | +40.77% | ||
| 3 months | +5.62% | ||
| 6 months | +0.24% | ||
| Current year | -9.32% |
1 week
7 900.00
9 450.00
1 month
6 100.009 450.00
Current year
5 390.0011 580.00
1 year
5 390.0032 000.00
3 years
4 970.0032 000.00
5 years
4 970.0032 000.00
10 years
4 970.0032 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yu-Jin Seo
CEO | Chief Executive Officer | 55 | 13-06-30 |
Won-Jae Lee
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sa-Cheol Hong
BRD | Director/Board Member | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sa-Cheol Hong
BRD | Director/Board Member | 66 | - |
Yu-Jin Seo
CEO | Chief Executive Officer | 55 | 13-06-30 |
Young-Won Park
BRD | Director/Board Member | 54 | 17-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-26 | 8,460 | -7.14% | 163,667 |
| 24-06-25 | 9,110 | +0.66% | 152,283 |
| 24-06-24 | 9,050 | +11.04% | 938,678 |
| 24-06-21 | 8,150 | 0.00% | 96,920 |
| 24-06-20 | 8,150 | +0.99% | 175,210 |
End-of-day quote Korea S.E., June 25, 2024
More quotes
GeneSystem Co Ltd is a Korea-based company principally engaged in the development and manufacture of molecular diagnostic solutions. The Company is engaged in the development, manufacture and sale of platform based on molecular diagnosis. The Company develops and manufactures products such as molecular diagnosis systems, biochips, test kits, and reaction reagents, among others. The Company develops in vitro diagnostic technology through immunodiagnosis technology and molecular diagnosis technology.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.32% | 42.59M | |
| -9.59% | 11.57B | |
| -12.79% | 7.37B | |
| +26.65% | 5.44B | |
| -17.87% | 3.74B | |
| +7.41% | 2.58B | |
| -65.15% | 2.33B | |
| +28.63% | 2.23B | |
| -11.56% | 2.21B | |
| -14.32% | 1.67B |
- Stock Market
- Equities
- A363250 Stock
